[1]周爱萍.重组人干扰素α-2b注射液联合凝胶对宫颈HPV感染患者炎性因子水平的影响[J].医学信息,2022,35(06):162-164.[doi:10.3969/j.issn.1006-1959.2022.06.042]
　ZHOU Ai-ping.Effect of Recombinant Human Interferon α-2b Injection Combined with Gel on Inflammatory Factor Levels in Patients with Cervical HPV Infection[J].Medical Information,2022,35(06):162-164.[doi:10.3969/j.issn.1006-1959.2022.06.042]
点击复制

重组人干扰素α-2b注射液联合凝胶对宫颈HPV感染患者炎性因子水平的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年06期
页码:
162-164
栏目:
药物与临床
出版日期:
2022-03-15

文章信息/Info

Title:
Effect of Recombinant Human Interferon α-2b Injection Combined with Gel on Inflammatory Factor Levels in Patients with Cervical HPV Infection
文章编号:
1006-1959（2022）06-0162-03
作者:
周爱萍
（天津港口医院妇产科，天津 300456）
Author(s):
ZHOU Ai-ping
(Department of Obstetrics and Gynecology,Tianjin Port Hospital,Tianjin 300456,China)
关键词:
人乳头瘤病毒; 重组人干扰素α-2b; 炎性因子; 阴道微生态
Keywords:
Human papilloma virus; Recombinant human interferon α-2b; Inflammatory factor; Vaginal microecology
分类号:
R75
DOI:
10.3969/j.issn.1006-1959.2022.06.042
文献标志码:
A
摘要:
目的 研究重组人干扰素α-2b（INFα-2b）注射液联合凝胶对宫颈人乳头瘤病毒（HPV）感染患者炎性因子水平的影响。方法 选取2020年2月-2021年2月我院收治的88例宫颈HPV感染患者，依据随机数字表法分为对照组与观察组，各44例。对照组给予INFα-2b凝胶外用治疗，观察组在对照组基础上联合INFα-2b注射液治疗，比较两组宫颈HPV转阴效果、阴道微生态情况、炎性因子（IL-4、IL-12、TNF-α）、免疫功能（IFN-γ、CD4+/CD8+）。结果 观察组HPV转阴率及有效率高于对照组，差异有统计学意义（P＜0.05）；两组治疗后阴道分泌物pH值、Nugent评分低于治疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）；两组治疗后IL-4、TNF-α水平低于治疗前，IL-12水平高于治疗前，且观察组IL-4、TNF-α水平低于对照组，IL-12水平高于对照组，差异有统计学意义（P＜0.05）；两组治疗后IFN-γ、CD4+/CD8+水平高于治疗前，且观察组高于对照组，差异有统计学意义（P＜0.05）。结论 INFα-2b注射液联合凝胶可提高宫颈HPV转阴率，改善阴道微生态环境，同时降低炎性反应，提升免疫功能。
Abstract:
Objective To study the effect of recombinant human interferon α-2b (INFα-2b) injection combined with gel on the levels of inflammatory factors in patients with cervical human papilloma virus (HPV) infection.Methods A total of 88 patients with cervical HPV infection admitted to our hospital from February 2020 to February 2021 were selected and randomly divided into control group and observation group, with 44 cases in each group. The control group was treated with INFα-2b gel for external use, and the observation group was treated with INFα-2b injection on the basis of the control group. The negative conversion effect of cervical HPV, vaginal microecology, inflammatory factors (IL-4, IL-12, TNF-α), and immune function (IFN-γ, CD4+/CD8+) were compared between the two groups.Results The negative conversion rate and effective rate of HPV in the observation group were higher than those in the control group, and the difference was statistically significant (P<0.05). After treatment, the pH value and Nugent score of vaginal secretion in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group, the difference was statistically significant (P<0.05). The levels of IL-4 and TNF-α in the two groups after treatment were lower than those before treatment, the level of IL-12 was higher than that before treatment, and the levels of IL-4 and TNF-α in the observation group were lower than those in the control group, and the level of IL-12 was higher than that in the control group, the difference was statistically significant (P<0.05). The levels of IFN-γ and CD4+/CD8+ in the two groups after treatment were higher than those before treatment, and the observation group was higher than the control group, the difference was statistically significant (P<0.05).Conclusion INFα-2b injection combined with gel can improve cervical HPV negative conversion rate, improve vaginal microecological environment, reduce inflammatory reaction and improve immune function.

参考文献/References:

[1]王璐,黄晓桃,葛曼,等.重组人干扰素α-2b凝胶联合乳酸菌阴道胶囊对宫颈高危型HPV持续感染的治疗[J].中国微生态学杂志,2020,32(12):1449-1453.[2]Ye H,Song T,Zeng X,et al.Association between genital mycoplasmas infection and human papillomavirus infection, abnormal cervical cytopathology, and cervical cancer: a systematic review and meta-analysis[J].Arch Gynecol Obstet,2018,297(6):1377-1387.[3]陈栋.重组人干扰素α-2b凝胶联合ALA-PDT治疗尖锐湿疣的疗效及复发率分析[J].皮肤病与性病,2021,43(3):360-361.[4]苏小玉,蒙莉萍,邹聪聪,等.重组人干扰素凝胶联合保妇康栓治疗宫颈高危型HPV感染的临床观察[J].中国药房,2020,31(8):984-988.[5]梁沙沙.重组人干扰素α-2b凝胶治疗慢性宫颈炎合并高危型HPV感染的临床效果[J].河南医学研究,2018,27(24):4509-4510.[6]黄慧,杨芳,程丽琴,等.重组人干扰素α-2b对宫颈高危人类乳头瘤病毒(HPV)感染患者HPV清除率及免疫功能的影响[J].吉林医学,2018,39(11):2137-2138.[7]马红,许辉,顾文涛,等.5α-氨基酮戊酸联合重组人干扰素α-2b凝胶治疗女性尖锐湿疣合并宫颈高危HPV感染[J].中国热带医学,2018,18(11):1079-1082.[8]徐弦珍.重组人干扰素-α2b阴道泡腾胶囊对宫颈人乳头瘤病毒感染患者的临床疗效评价[J].抗感染药学,2018,15(7):1238-1239.[9]李月菊.HPV联合TCT检测对宫颈病变诊断的预测价值[J].广州医药,2021,52(3):48-51.[10]刘佳,芦维园,韩旭.重组人干扰素α-2b凝胶辅助Leep刀在宫颈HPV感染中的治疗效果[J].中国妇幼保健,2018,33(11):2604-2606.[11]孙宁.重组人干扰素治疗宫颈HPV感染患者的临床疗效分析[J].现代诊断与治疗,2020,31(4):535-536.[12]冯小丽,刘继红,李聪.重组人干扰素α-2b与保妇康栓阴道放置对宫颈高危HPV感染患者的疗效及免疫功能的影响[J].河北医药,2018,40(7):1083-1085.[13]宁瑶.重组人干扰素α-2b凝胶治疗慢性宫颈炎并发高危型HPV感染的临床研究[J].中国处方药,2018,16(3):48-49.[14]金英慧,王帅.重组人干扰素治疗宫颈高危型HPV感染的有效性[J].中国继续医学教育,2018,10(3):120-122.[15]蒙霞.保妇康栓与重组人干扰素α-2b凝胶治疗慢性宫颈炎伴HPV感染的临床疗效[J].现代诊断与治疗,2017,28(6):1096-1097.[16]胡莉琴,赖晓莉,李梅,等.重组人干扰素α-2b凝胶对慢性宫颈炎合并HPV感染患者炎症因子及免疫功能的影响[J].中国地方病防治杂志,2016,31(9):1068.[17]陈思凯,史宏晖,冷金花.宫颈HPV感染与阴道内细菌微环境/免疫微环境的关系[J].生殖医学杂志,2019,28(6):711-716.[18]余杨,孙翔.Th1/Treg细胞失衡对宫颈癌临床分期的作用[J].实用医学杂志,2016,32(6):999-1001.

相似文献/References:

[1]莫宗平,刘 巧,蒋佳利.安岳地区女性高危型HPV基因分型结果分析[J].医学信息,2018,31(18):101.[doi:10.3969/j.issn.1006-1959.2018.18.031]
　MO Zong-ping,LIU Qiao,JIANG Jia-li.Analysis of the Results of High-risk HPV Genotyping in Women in Anyue Area[J].Medical Information,2018,31(06):101.[doi:10.3969/j.issn.1006-1959.2018.18.031]
[2]邬素珍,许焕英.宫颈人乳头瘤病毒感染的免疫研究进展[J].医学信息,2018,31(19):33.[doi:10.3969/j.issn.1006-1959.2018.19.012]
　WU Su-zhen,XU Huan-ying.Progress in Immunization of Cervical Human Papillomavirus Infection[J].Medical Information,2018,31(06):33.[doi:10.3969/j.issn.1006-1959.2018.19.012]
[3]穆红茹.中晚期宫颈癌的非手术治疗进展[J].医学信息,2022,35(15):167.[doi:10.3969/j.issn.1006-1959.2022.15.040]
　MU Hong-ru.Advances in Nonsurgical Treatment of Cervical Cancer in the Middle and Late Stage[J].Medical Information,2022,35(06):167.[doi:10.3969/j.issn.1006-1959.2022.15.040]
[4]许生样.杭州地区男性人乳头瘤病毒感染特征分析[J].医学信息,2020,33(05):137.[doi:10.3969/j.issn.1006-1959.2020.05.043]
　XU Sheng-yang.Characteristics of Human Papillomavirus Infection in Male in Hangzhou[J].Medical Information,2020,33(06):137.[doi:10.3969/j.issn.1006-1959.2020.05.043]
[5]秦燕,王杏茶,方淑琴,等.承德市女性人乳头瘤病毒感染基因分型的临床分析[J].医学信息,2020,33(08):144.[doi:10.3969/j.issn.1006-1959.2020.08.047]
　QIN Yan,WANG Xing-cha,FANG Shu-qin,et al.Infection Status and Distribution Characteristics of Female HPV Subtypes in Chengde City from 2014 to 2017[J].Medical Information,2020,33(06):144.[doi:10.3969/j.issn.1006-1959.2020.08.047]
[6]代艳文,吴大富.宜昌地区妇女人乳头瘤病毒感染状况分析[J].医学信息,2020,33(16):143.[doi:10.3969/j.issn.1006-1959.2020.16.045]
　DAI Yan-wen,WU Da-fu.Analysis of Women’s Human Papillomavirus Infection in Yichang Area[J].Medical Information,2020,33(06):143.[doi:10.3969/j.issn.1006-1959.2020.16.045]
[7]翁梦晴,韦彩萍,任文宁,等.基于CiteSpace的人乳头瘤病毒疫苗可视化分析[J].医学信息,2023,36(03):39.[doi:10.3969/j.issn.1006-1959.2023.03.009]
　WENG Meng-qing,WEI Cai-ping,REN Wen-ning,et al.Visual Analysis of Human Papillomavirus Vaccine Based on CiteSpace[J].Medical Information,2023,36(06):39.[doi:10.3969/j.issn.1006-1959.2023.03.009]
[8]毛 焕,潘建立,王长友.NLRP3炎症小体基因在HPV感染子宫颈细胞中的表达差异研究[J].医学信息,2023,36(06):114.[doi:10.3969/j.issn.1006-1959.2023.06.025]
　MAO Huan,PAN Jian-li,WANG Chang-you.Differential Expression of NLRP3 Inflammasome Gene in HPV-infected Cervical Cells[J].Medical Information,2023,36(06):114.[doi:10.3969/j.issn.1006-1959.2023.06.025]
[9]李芳芳,于 佳.重组人干扰素α-2b雾化治疗儿童呼吸道病毒感染性疾病的临床效果[J].医学信息,2021,34(23):120.[doi:10.3969/j.issn.1006-1959.2021.23.035]
　LI Fang-fang,YU Jia.Clinical Effect of Recombinant Human Interferon α-2b Atomization in the Treatment of Children with Respiratory Viral Infectious Diseases[J].Medical Information,2021,34(06):120.[doi:10.3969/j.issn.1006-1959.2021.23.035]
[10]张 晴,杨勇莉.p16在宫颈癌发生发展中的作用[J].医学信息,2022,35(01):59.[doi:10.3969/j.issn.1006-1959.2022.01.014]
　ZHANG Qing,YANG Yong-li.Role of p16 in the Development of Cervical Cancer[J].Medical Information,2022,35(06):59.[doi:10.3969/j.issn.1006-1959.2022.01.014]

更新日期/Last Update: 1900-01-01